Using Artificial Intelligence To Predict Cancer Progression

Cancer progression prediction uses artificial intelligence (AI) to estimate how a tumour may change over time, how likely it is to return, or how a patient may respond to treatment. These tools draw on clinical records, medical imaging, pathology, genomics, treatment history, and patient-reported information to identify patterns that can be difficult to detect through standard assessment alone.

The goal is not to replace oncologists, nurses, pathologists, or patients in decision-making. It is to support earlier risk assessment, more personalised care, and better use of limited clinical resources. For a research translation network, the important question is whether a promising algorithm can be tested safely and converted into measurable improvements in health outcomes.

Artificial intelligence must therefore be viewed as part of a broader health system. Its value depends on reliable data, representative research participants, appropriate governance, clinician confidence, and clear communication with patients and families.

What Cancer Progression Prediction Means

Progression can refer to several different events: a tumour growing during treatment, cancer spreading to another organ, disease returning after remission, or a patient experiencing a decline that requires a change in care. An AI model must define the outcome it is predicting before it can be judged properly.

Some systems estimate an individual’s risk over a specified period, such as twelve months. Others analyse scans over time to detect subtle changes in tumour volume or structure. Predictive models may also identify patients who are more likely to benefit from a therapy, need closer monitoring, or require referral to supportive and palliative care services.

These distinctions matter because a prediction is not the same as a diagnosis. A high-risk result indicates that further clinical assessment may be useful; it should not determine treatment automatically. The model’s output must be interpreted alongside pathology, patient preferences, comorbidities, treatment goals, and the expertise of the care team.

Signals AI Can Combine

Medical imaging is one of the most visible applications of AI in oncology. Deep learning models can examine CT, MRI, PET, ultrasound, or digital pathology images for features associated with aggressive disease. Radiomics extends this approach by measuring texture, shape, intensity, and spatial relationships that may not be obvious during routine visual review.

Other models combine imaging with molecular and clinical data. Genomic alterations, circulating tumour DNA, blood test results, medication history, age, functional status, and previous treatment can create a richer picture of disease behaviour. Longitudinal records are particularly valuable because progression is a process, rather than a single event at diagnosis.

Integrated partnerships are important when data comes from different services and settings. Lessons from chronic disease partnerships show why consistent definitions, shared infrastructure, and collaboration between researchers and clinicians are essential for turning complex evidence into practical care.

From Model Output To Clinical Decision

A useful prediction should lead to an appropriate action. For example, a patient identified as having a high probability of recurrence might receive a more personalised surveillance schedule, additional imaging, molecular testing, or discussion by a multidisciplinary tumour board. A lower-risk estimate might help avoid unnecessary procedures, provided the model has been thoroughly validated.

Performance is usually described using measures such as sensitivity, specificity, calibration, and area under the receiver operating characteristic curve. These statistics are helpful, but they do not answer every clinical question. A model can perform well in a research dataset and still fail when used in a different hospital, population, scanner, or treatment era.

Translating Research Into Real Care

Moving from a prototype to clinical practice requires prospective evaluation. Researchers need to test whether the model improves decisions and patient outcomes, rather than simply predicting progression accurately. Relevant outcomes may include earlier detection of relapse, fewer avoidable investigations, improved quality of life, better treatment selection, and equitable access to care.

Implementation also involves workflow design. Clinicians need to know when the prediction is generated, who reviews it, how uncertainty is displayed, and what action is available. If an alert appears without a defined response, it can create noise rather than benefit. Education, technical support, and feedback loops help teams understand when the model is useful and when professional judgement should override it.

The Brisbane Diamantina network provides a useful context for this kind of translation because health services, universities, research institutes, and communities can contribute different forms of expertise. Collaboration can connect algorithm development with ethics, implementation science, consumer engagement, and evaluation of real-world outcomes.

Equity, Safety, And Governance

AI can reproduce inequalities that exist in its training data. If a model is developed mainly from patients at large metropolitan hospitals, it may be less accurate for rural communities, culturally diverse populations, older adults, or people whose records contain fewer tests. Differences in scanner technology, referral pathways, access to treatment, and documentation can also affect performance.

Cancer prediction systems require strong privacy protections because they use highly sensitive health and genetic information. Governance should address consent, data access, cybersecurity, retention, commercial interests, and responsibility for errors. Patients should receive understandable information about how AI contributes to their care and whether a clinician remains responsible for the final decision.

Human impact deserves attention as well. Risk estimates can cause anxiety, particularly when the prediction is uncertain or cannot be acted upon immediately. Communication should explain probability in plain language, distinguish risk from certainty, and provide access to appropriate support. Research involving young people and families, including mental health evidence, illustrates the importance of translating evidence with sensitivity to lived experience.

Practical Priorities For Responsible Use

Health organisations considering AI for cancer progression should begin with a clearly defined clinical need rather than adopting technology because it is novel. The following priorities can support a safer and more useful pathway:

• Define the prediction target, intended users, timeframe, and clinical action before model development.
• Validate performance across hospitals, demographic groups, disease subtypes, and relevant treatment pathways.
• Measure clinical utility, patient outcomes, workflow effects, and equity alongside technical accuracy.
• Build explainable reporting, human oversight, patient communication, and escalation processes into the system.
• Monitor the model after deployment for drift, bias, unexpected errors, and changes in clinical practice.

A staged approach is preferable to immediate widespread deployment. Retrospective studies can identify promising signals, prospective studies can test performance in real settings, and controlled implementation evaluations can determine whether the tool improves care. Results should be published transparently, including negative findings and limitations.

Cancer progression prediction will be most valuable when it strengthens clinical relationships rather than reducing patients to scores. Researchers, clinicians, consumers, carers, and communities can work together to decide which predictions are meaningful and what responsible use looks like. Explore opportunities for collaboration, research translation, and evidence-based innovation through Brisbane Diamantina Health Partners.